Award
National Cancer Institute 5R21CA300631-02
MYCN drives a suppressive tumor immune microenvironment in neuroblastoma.
Recipient
Not Specified
Award Amount
$187,584.00
Ceiling
$187,584.00
Awarded
March 19, 2026
Identifier
5R21CA300631-02
Award for research on MYCN's role in neuroblastoma immune evasion funded by the National Cancer Institute under NIH grant PAR-22-216.
Description
The project focuses on understanding how MYCN reprograms tumor metabolism to drive immune evasion in neuroblastoma. The award is part of NIH grant PAR-22-216. The project duration is from April 10, 2025, to March 31, 2027. The funding is provided by the National Cancer Institute.